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Background: High-dose chemotherapy (HDC) with hematopoietic progenitor cell transplantation is a standard option for
relapsed/refractory testicular germ-cell tumor (GCT), but only few data have been reported in female patients with GCT. We con-
ducted a retrospective analysis of female patients with GCT treated with HDC and registered with the European Society for
Blood and Marrow Transplantation.
Patients and methods: Between 1985 and 2013, 60 registered female patients with GCT, median age 27 years (range 15–48),
were treated with salvage HDC. Forty patients (67%) had primary ovarian GCT, 8 (13%) mediastinal, 7 (12%) retroperitoneal and
5 (8%) other primary sites/unknown. Twenty-two patients (37%) received HDC as second-line therapy, 29 (48%) as third-line, and
9 (15%) as fourth- to sixth-line. Nine of 60 patients (15%) received HDC as late-intensification with no evidence of metastasis
before HDC. The conditioning HDC regimens comprised carboplatin in 51 of 60 cases (85%), and consisted of a single HDC cycle
in 31 cases (52%), a multi-cycle HDC regimen in 29 (48%).
Results: Nine cases who underwent late intensification HDC were not evaluable for response. Of the other 51 assessable
patients, 17 (33%) achieved a complete response (CR), 8 (16%) a marker-negative partial remission (PRm), 5 (10%) a marker-
positive partial remission, 5 (10%) stable disease, and 13 (25%) progressive disease. There were 3 toxic deaths (6%). With an over-
all median follow-up of 14 months (range 1–219), 7 of 9 (78%) patients with late intensification and 18 of the 25 patients (72%)
achieving a CR/PRm following HDC were free of relapse/progression. In total, 25 of 60 patients (42%) were progression-free fol-
lowing HDC at a median follow-up of 87 months (range 3–219 months).
Conclusions: Salvage HDC based on carboplatin represents a therapeutic option for female patients with relapsed/refractory
GCT.
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Introduction
Malignant ovarian germ-cell tumors (GCT) are rare accounting
for nearly 2%–3% of all ovarian tumors and occurring with an
age-adjusted incidence rate of 0.3 per 100 000 adolescent and
young women with a median age of nearly 20–25 years [1]. Most
female patients with GCT achieve sustained remissions following
first-line cisplatin-based chemotherapeutic regimens, but a small
percentage progress and is commonly treated with ifosfamide
and cisplatin-based chemotherapeutic regimens mirroring regi-
mens used for men with relapsed GCT [2, 3]. High-dose chemo-
therapy (HDC) with peripheral blood progenitor cell (PBPC)
support is an accepted and feasible option for salvage treatment
in male patients with relapsed GCT taking into consideration
large series of retrospective data [4, 5]. HDC is considered an op-
tion together with other standard-dose regimens as second-line
therapy and represents the treatment with the highest chance of
cure as third-line or subsequent therapy for these patients [5, 6].
Moreover, in children with relapsed GCT HDC showed impres-
sive results and is considered a possible option as salvage treat-
ment [7]. A few small series have reported salvage HDC in female
patients with relapsed/refractory GCTs [8, 9].
We conducted a retrospective analysis of female patients with
GCT treated with salvage HDC registered with the European
Society for Blood and Marrow Transplantation (EBMT).
Methods
Data collection
From 1985 to 2013, a total of 114 patients aged15 years with a diagnosis
of female GCT were registered with the EBMT. Female GCT may include
dysgerminomas and non-dysgerminomas. Non-dysgerminomas were
classified as embryonal carcinoma, choriocarcinoma, yolk sac tumor, im-
mature teratoma, and mixed GCT, according to the World Health
Organization classification. Patients with a non-ovarian primary tumor
site (extragonadal GCT) were included, whereas patients with gestational
trophoblastic neoplasms (e.g. gestational choriocarcinoma) were
excluded from this report. The registration details of these patients were
reviewed, and the reporting physicians were contacted and asked to pro-
vide further information on histology, tumor markers, initial treatment,
standard chemotherapy, HDC regimens and toxicities, PBPC and/or au-
tologous bone marrow transplantation (BMT) support, follow-up and
data on possible secondary neoplasms. For data collection, a standardized
questionnaire was sent to each center. Of 114 registered cases, 60 ques-
tionnaires were returned (redemption rate, 53%) from 25 centers in
Europe.
Definitions
Tumor response was classified as follows. A complete remission (CR) was
defined as a complete disappearance of all clinical, radiological and bio-
chemical evidence of disease. A partial response (PR) was defined as a de-
crease in 50% or more of the sum of the products of perpendicular
diameters of measurable disease, with a decrease of 90% of tumor
markers, including normalization of tumor markers considered as a par-
tial remission with tumor marker normalization (PRm–) and without
complete normalization considered as a marker positive partial remission
(PRmþ). Stable disease (SD) was defined as a decrease <50% or an in-
crease <25% in bidimensional tumor measurements or stable tumor
marker levels. Progressive disease (PD) was defined as either residual
lesions increasing in size or as occurrence of new lesions and/or elevation
of tumor markers.
Statistical analysis
Descriptive statistics are presented as count and relative frequency for
categorical data and the median and range for continuous data. Overall
survival (OS) was defined as the time from HDC to death from any cause
or last follow-up, and progression-free survival (PFS) was defined as the
time from HDC to relapse or PD or death from any cause, whatever came
first, or last to follow-up. Probabilities of OS and PFS were estimated
using the Kaplan–Meier product limit method and were compared using
the log-rank test. A P value of <0.05 was considered to be significant.




Between 1985 and 2013, 60 registered female patients with GCT
aged 15 years were treated with salvage HDC, median age was
27 years (range 15–48). Thirty-eight (63%) patients had primary
ovarian GCT, 11 (18%) mediastinal, and 11 (18%) other extra-
gonadal primary sites. Fifty-nine (98%) patients received at least
one cisplatin-based chemotherapy before HDC, while one (2%)
15-year-old girl received carboplatin-based chemotherapy only
before HDC. Details of the patient characteristics before HDC are
listed in Table 1.
Salvage treatment
Between 1985 and 1990, 11 (18%) patients were treated with 15
courses of a HDC regimen, between 1991 and 2000 23 (38%) pa-
tients received 30 courses, and 2001 and 2013 26 (43%) patients
45 courses. Twenty-two patients (37%) received HDC as second-
line therapy, 29 (48%) as third-line, and 9 (15%) as fourth- to
sixth-line. Nine of 60 (15%) patients received HDC as late-
intensification of a previous regimen without evidence of metas-
tasis at the time of HDC. The planned conditioning HDC
regimens consisted of a single cycle in 31 cases (52%) and a
multi-cycle regimen in 29 (48%), consisting of 2 HDC cycles in
25 cases and 3 HDC cycles in 4. However, in 2 cases the second
planned HDC cycle was not carried out due to toxic death after
the first one, so totally 90 HDC cycles were administered. The
most commonly used HDC regimens were based on high-doses
of carboplatin and etoposide, with or without another high-dose
chemotherapeutic agent and comprised carboplatin in 51 of 60
cases (85%) (Table 2). Before HDC, 37 (62%) patients received
an induction and/or mobilizing regimen, more frequently VIP
(cisplatin, etoposide and ifosfamide) (n¼ 15, 41%), while 23
(28%) patients were treated with up-front HDC. In total, 61
courses in 37 patients were supported by PBPC reinfusion, 28
courses in 22 patients were supported by BM reinfusion, and 1
course was supported by both BM and PBPC reinfusion.
Response and survival
Nine cases who underwent late intensification HDC were not
evaluable for response. Of other 51 patients treated with salvage
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HDC at PD from a previous line of therapy, 24 (47%) obtained
an objective response, including 15 (29%) CR and 9 (18%)
PRm, 5 (10%) patients achieved PRmþ, 5 (10%) SD, 13 (25%)
PD, 1 (1%) case was considered not evaluable for response,
whereas in 3 (6%) cases treatment-related deaths occurred. Of 9
patients with PRm after HDC, 6 (67%) received the surgical re-
section of residual masses, in 4 cases without evidence of viable
malignant cells in the histological specimen (pathological CR),
and in the other 2 with presence of viable malignant cells (surgical
CR). In one case with pathological CR, a post-surgical adjuvant
retroperitoneal radiotherapy was given. Treatment-related death
occurred in three patients treated with HDC supported by ABMT
in 1988, 1989, and 1994, respectively; all these three cases had a
cisplatin-refractory ovarian GCT, defined as PD as best response
to previous cisplatin-based chemotherapy.
With a median follow-up time for all patients of 14 months
(range 1–219 months), 7 of 9 (78%) patients who underwent late
intensification and 18 of the 24 patients (72%) who achieved an
objective response following HDC were alive free of relapse/pro-
gression. Overall, with at a median follow-up period for surviving
cases of 84 months (range 3–219 months), 25 (42%) of 60 pa-
tients were continuously progression-free following HDC,
including 7 treated with late intensification HDC, while 26 (44%)
were alive following HDC, 13 (59%) of 22 treated as initial sal-
vage setting and 13 (34%) of 38 at later stages. The median PFS
time was 9 months (95% CI 4.3–not reached) and the median OS
time was 27.6 months (95% CI 8.9–48.5). The 3-year OS rate for
these patients was 43%. Figure 1 shows Kaplan–Meier estimates
of PFS and OS for these patients.
The response rate and the clinical outcome of patients was dif-
ferent according to the gonadal or extragonadal GCT primary
site (Table 3). The median PFS time was 19.2 months (95% CI
4.3–not reached) for patients with primary ovarian GCT,
11.8 months (95% CI 1.9–not reached) for extragonadal non-
mediastinal primary GCT and 6.9 months (95% CI 1.0–20.9) for
patients with mediastinal primary site (P¼ 0.175). The median
OS time was 30.8 months (95% CI 9.1–not reached) for patients
with primary ovarian GCT, 27.6 months (95% CI 4.5–not
reached) for extragonadal non-mediastinal primary GCT and
7.4 months (95% CI 5.2–47.0) for patients with mediastinal pri-
mary site (P¼ 0.100). The 3-year OS rates for these three groups
of patients were 47%, 31%, and 23%, respectively. There was not
difference in the median PFS and OS among patients treated with
single or multicycle HDC regimens (data not shown), however,
several HDC regimens were used and for every HDC regimen one
or more cycles were administered (Table 2).
In patients treated with HDC as second-line therapy, the me-
dian PFS and OS time was not reached, whereas in those treated
Table 1. Patient characteristics before high-dose chemotherapy
Characteristics n (%)
Age, years




Mediastinum and retroperitoneum 2 (3%)
Retroperitoneum 4 (7%)
Sigmoid colon 2 (3%)
Pineal/pituitary gland 1 (2%)
Other/unknown 4 (7%)
Histological type
Yolk sac tumor 20 (33%)
Embryonal carcinoma 9 (15%)
Non-dysgerminoma—mixed form 9 (15%)
Non-gestational choriocarcinoma 7 (12%)
Dysgerminoma 3 (10%)
Other/unknown 12 (20%)







HDC line of therapy
2nd line 22 (37%)
3rd line 29 (48%)
4th to 6th line 9 (15%)
HDC setting
HDC at PD after a previous CT 51 (85%)





Single cycle 31 (52%)
Multi-cycle 29 (48%)
Hematopoietic support
Peripheral blood progenitor cells 37 (62%)
Bone marrow transplantation 22 (37%)
Both PBPC and BMT 1 (2%)
HDC, high-dose chemotherapy; CT, chemotherapy; PBPC, peripheral
blood progenitor cells; BMT, bone marrow transplantation.
Table 2. Details of high-dose chemotherapy regimens






21 (17%) 25 (17%)
Carboplatin–etoposide–
ifosphamide
14 (33%) 24 (33%)
Carboplatin–etoposidea 13 (33%) 22 (33%)
Carboplatin–etoposide–thiotepa 3 (25%) 3 (25%)
Thiotepa–paclitaxel 3 (25%) 7 (25%)
Thiotepa–cyclophasphamide 2 (25%) 3 (25%)
Etoposide–ifosfamide–cisplatin 2 (25%) 3 (25%)
Etoposide–ifosfamide 1 (25%) 2 (25%)
Melphalan–etoposide 1 (25%) 1 (25%)
aIn a patient, in two courses of CE, vinblastine was given in addition.
HDC, high-dose chemotherapy.
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as third or further line of therapy the median PFS time was
5.8 months (95% CI 2.15–11.8), P¼ 0.031, while the median
OS time was 11.2 months (95% CI 7.0–27.9), P¼ 0.035. Figure 2
illustrates PFS and OS according to the primary site, and the
number of previous line of therapies.
All three patients with dysgerminoma had primary ovarian
GCT and with HDC achieved CR, PRm, and SD, respectively,
but none maintained a disease-free status and all three patients
died within one year from HDC.
No cases of secondary leukemia or myelodysplasia were re-
ported in these patients, but one case of breast cancer occurred in
a woman aged<35 years in a disease-free status from GCT after
HDC.
Discussion
Due to the rarity of the disease and the high curability in the pri-
mary setting, there are limited cases series on the salvage treat-
ment of female patients with relapsed/refractory GCT. To our
knowledge, the 60 female patients who received salvage HDC in
our study represents the largest group yet reported in this setting.
In the EBMT experience, salvage HDC appeared active in female
GCT patients with 43% alive and progression-free at a median
follow-up of 7 years in surviving patients, whereas long-term sur-
vival was reported in only 10% of patients treated with standard-
dose salvage chemotherapy in the major retrospective series [3].
Yolk sac histology was the
prevalent histology in relapsed/progressing patients in our ser-
ies as well as other major ones [8, 10]. Extragonadal GCT ac-
counts for nearly 10% of all female GCT in adolescent and young
women [11], but in our series focused on relapsed/progressing
patients the extragonadal GCT accounted for the 37%, confirm-
ing the poor prognosis of this subset of patients. Toxic death
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Figure 1. Kaplan–Meier estimates of progression-free survival (A)
and overall survival (B).
Table 3. Response and outcome according to primary tumor site
Primary site
Total Gonadal Mediastinum Extra-gonadal
non-mediastinal
(n560) (n538) (n511) (n511)
[n (%)] [n (%)] [n (%)] [n (%)]
Response
Complete remission 15 (25%) 9 (24%) 2 (18%) 4 (36%)
Partial remission with negative marker 9 (15%) 5 (13%) 2 (18%) 2 (18%)
Partial remission with positive marker 5 (8%) 2 (5%) 2 (18%) 1 (9%)
Stable disease 5 (8%) 4 (11%) 0 1 (9%)
Progressive disease 13 (22%) 6 (16%) 4 (36%) 3 (27%)
Treatment-related death 3 (6%) 3 (8%) 0 0
Not evaluable 1 (2%) 0 1 (9%) 0
Late intensification 9 (15%) 9 (24%) 0 0
Outcome
Alive continuously disease-free 25 (42%) 19 (50%) 2 (18%) 4 (36%)
Alive currently disease-free 0 0 0 0
Alive with disease 1 (2%) 0 0 1 (9%)
Dead of disease 31 (52%) 16 (42%) 9 (82%) 6 (55%)
Treatment-related death 3 (5%) 3 (8%) 0 0
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support without colony-stimulating factors between 1986 and
1990, and 1 of 23 (4%) treated with HDC and BM support be-
tween 1991 and 2000, whereas no cases of HDC-related death
occurred in the 26 cases treated with HDC after 2001. The high
treatment-related mortality (18%) that occurred in our patient
series in the 1980s was similar to the mortality observed in other
major series during the same period [12–15]. However, with im-
proved patient selection and supportive care, the HDC-related
mortality decreased to 4% in the 1990s and no cases in 2000s.
One case of breast cancer occurred, whereas no patient developed
myelodysplasia or secondary leukemia after receiving HDC.
Patients with mediastinal primary GCT had not statistically
significantly different PFS and OS from those with other primary
sites, however, a significant trend for poorer PFS and OS was ap-
parent (Figure 2A and B). Furthermore, only 11 patients had a
mediastinal primary GCT which likely contributed to the low
statistical power in this tumor characteristic. Mediastinal primary
site is recognized as a poor risk factor in male patients with non-
seminomatous GCT not only at diagnosis [16, 17], but also be-
fore salvage chemotherapy where represents the poorest
prognostic factor [18, 19]. Larger case series are needed to verify
the potential impact of mediastinal primary site in the prognosis
of female patients with GCT. Results with HDC in other
extragonadal GCT patient populations, as first-line late intensifi-
cation in male patients [17], and as salvage treatment in extrago-
nadal GCT in children [7] confirmed the activity of HDC even in
these extragonadal GCT patients, but the impact of HDC in me-
diastinal primary GCT remains controversial. We also evaluated
patients treated with HDC as second-line therapy versus those
treated as third or further line of therapy, the median PFS and OS
were statistically significantly different confirming a better out-
come for patients treated with HDC as first salvage option
(Figure 2C and D). Different HDC regimens were administered
with different number of cycles (Table 2), so an analysis of the im-
pact on the clinical outcome of different regimens and/or the
number of HDC cycles was not possible. However, in male pa-
tients with GCT modern HDC regimens are based on two or
three cycles of high-dose carboplatin and etoposide, so these mul-
ticycle HDC regimens should be adopted for salvage treatment of
female GCT [6, 20].
Limitations to this study are the retrospective nature, the lim-
ited number of cases in a large time period, the pathology was not
centrally reviewed and misclassification of tumors could have
occurred. However, our data provide evidence that patients with
recurrent female GCT can achieve long-term disease-free survival
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Figure 2. Kaplan–Meier estimates of progression-free survival and overall survival according to primary tumor site (A and B, respectively) or
according to the number of previous therapeutic lines (C and D, respectively). EG, extragonadal; n, number; mPFS, median progression-free
survival; mOS, median overall survival; n.r., not reached.
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salvage setting with 13 (59%) of 22 patients, but with long-term
PFS status also in 13 (34%) of 38 in whom HDC was attempted as
third-line or later treatment. Recently reported data from
Indiana University have shown long-term PFS in 3 (60%) of 5 fe-
male GCT patients treated with HDC as first salvage compared
with only 1 (13%) of 8 who received HDC with later stages [8].
Another recent experience from Memorial Sloan Kettering has
shown similar results with long-term PFS achieved in 4 (67%) of
6 female GCT patients who received HDC as initial salvage, and
in 2 (29%) of 7 patients as later salvage setting [9].
For female GCT, more effective treatments for poor prognosis
and relapsed advanced disease are needed. Randomized trials
evaluating new regimens in this setting might be conducted
only as a portion of male GCT studies with international collab-
oration [21].
In conclusion, this study suggests that salvage HDC represents
a valid therapeutic option for female patients with relapsed/re-
fractory GCT. Further collaborative retrospective studies are
needed to provide adequate data to try to define which relapsed
patients benefit most from salvage HDC. Female patients with
GCT should be included in phase II and III studies with HDC in
male patients with GCT to have the opportunity to provide pro-
spective data in this rare group of patients.
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